Advertisement

Increasing the Efficacy of 5-Fluorouracil with Interferons: Preclinical, Clinical, and Pharmacokinetic Studies

  • Joseph A. Sparano
  • Scott Wadler
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 339)

Abstract

The interferons are a family of glycoproteins which possess potent antiviral, immunomodulatory, and antiproliferative effects in vivo 1. The interferons also additively or synergistically enhance the efficacy of many cytotoxic agents against a number of cultured human adenocarcinoma, squamous cell carcinoma, and lymphoid tumor cell lines in vivo 1. In particular, interferon-α synergistically augments the antineoplastic effect of 5-fluorouracil (5-FU) in cultured human colonic adenocarcinoma cell lines in vivo.2 At the cellular level, the interferons act in a variety of ways to augment the antineoplastic effect of 5-FU by: (1) increasing the activity of thymidine Phosphorylase 3, thereby augmenting the anabolism of 5-FU to its active metabolite, fluorodeoxyuridylate monophosphate, (2) enhancing inhibition of thymidylate synthase, the target enzyme of 5-FU, at the post-transcriptional level 4, (3) inhibiting thymidine salvage pathways 3, and (4) by enhancing 5-FU induced DNA damage 5.

Keywords

Folinic Acid Advanced Colorectal Cancer Modulate Agent Human Colon Cancer Cell Line Antineoplastic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. Wadler and E.L. Schwartz, Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review, Cancer Res. 50: 3673 (1990).Google Scholar
  2. 2.
    S. Wadler, R. Wersto, V. Weinberg, D. Thompson, D., and E.L. Schwartz, Interaction f fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects, Cancer Res. 50: 5735 (1990).PubMedGoogle Scholar
  3. 3.
    E.L. Schwartz, M. Hoffman, C.J. O’Connor, and S. Wadler, Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells,. Biochemical and Biophysical Research Communications. 182: 1232 (1992).PubMedCrossRefGoogle Scholar
  4. 4.
    E. Chu, S. inn, D. Boarman, and C.J. Allegra, Interaction of interferon γ and 5-fluorouracil in the H630 human colon carcinoma cell line, Cancer Res. 50: 5834, (1990).PubMedGoogle Scholar
  5. 5.
    S. Wadler, X. Mao, and E.L. Schwartz, Recombinant alfa-2a-interferon augments 5-fluorouracil effects on nucleotide (dNTP) pools and DNA double strand breaks in human colon cancer cell lines, Proc Am Assoc Cancer Res. 33: 2539 (1992).Google Scholar
  6. 6.
    D. Goldstein and J. Laslo, Interferon therapy in cancer: from imaginon to interferon, Cancer Res. 46: 4315 (1986).PubMedGoogle Scholar
  7. 7.
    K. Morika, D. Fan, Y.M. Denkins, et al, Mechanisms of combined effects of γ-interferon and 5-fluorouracil on human colon cancers implanted into nude mice, Cancer Res. 49: 799 (1989).Google Scholar
  8. 8.
    J.M. Kirkwood and M.S. Ernstoff, Interferons in the treatment of human cancer, J Clin Oncol. 2: 336 (1984).PubMedGoogle Scholar
  9. 9.
    R.L. Stolfi, D.S. Martin, and R.C. Sawyer, Modulation of 5-fluorouracil-induced toxicity in mice with interferon or the interferon induce, polyinosinic-polycytidylic acid, Cancer Res. 43: 561 (1983).PubMedGoogle Scholar
  10. 10.
    S. Wadler and P.H. Wiernik, Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma, Semin Oncol. 17 (suppl 1): 16 (1990).PubMedGoogle Scholar
  11. 11.
    N. Kemeny, A. Younes, K. Sciter, et al, Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma: assessment of activity and toxicity, Cancer. 66: 2470 (1990).PubMedCrossRefGoogle Scholar
  12. 12.
    M. Huberman, E. McClay, M. Atkins, et al, Phase II trial of 5-fluorouracil and recombinant alpha interferon in advanced colorectal cancer, Proc Am Soc Clin Oncol. 10: 153 (1991).Google Scholar
  13. 13.
    E. Diaz Rubio, J. Jimeno, C. Camps, et al, Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis, Cancer Investigation. 10: 259, (1992).PubMedCrossRefGoogle Scholar
  14. 14.
    R. Pazdur, J.A. Ajani, Y.Z. Patt, et al, Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma, J Clin Oncol. 8: 2027 (1990).PubMedGoogle Scholar
  15. 15.
    H. Weh, D. Platz, D. Braumann, et al, Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: preliminary data of a phase II study, Semin Oncol. 19: 180 (1992).PubMedGoogle Scholar
  16. 16.
    J. Y. Douillard, J. Leborgne J. J.Y. Danielou, et al, Phase II trial of 5-fluorouracile (5-FU) and recombinant alpha interferon (rαIFN) (Intron A) in metastatic, previously untreated colorectal cancer, Proc Am Soc Clin Oncol. 10: 139 (1991).Google Scholar
  17. 17.
    A. Fornasiero, O. Daniele, C. Ghiotto, S.M.L Aversa, P. Morandi, and V. Florentino, Alpha-2 interferon and5-fluorouracil in advanced colorectal cancer, 1837X Tumor. 76: 385 (1990).Google Scholar
  18. 18.
    S. Wadler, B. Lembersky, M. Atkins, J. Kirkwoood, and N. Petrelli, Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study, J Clin Oncol. 9: 1806 (1991).PubMedGoogle Scholar
  19. 19.
    N. Petrelli, H.O. Douglass, Jr., L. Herrera, et al, The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial, J Clin Oncol. 7: 1419, 1989.PubMedGoogle Scholar
  20. 20.
    D.S. Martin, and N.E. Kemeny, Overview of N-Phosphonacetyl)-L-Aspartate + fluorouracil in clinical trials, Semin Oncol. 19: 228 (1992).PubMedGoogle Scholar
  21. 21.
    J. Schuller, M. Czejka, G. Schernthaner, U. Fogl, W. Jager, and M. Micksche, Influence of interferon α 2b with or without folinic acid on pharmacokinetics of fluorouracil, Semin Oncol. 19: 93 (1992).PubMedGoogle Scholar
  22. 22.
    Schuller, J, Personal Communication.Google Scholar
  23. 23.
    J.L. Grem, N. McAtee, R.F. Murphy, et al, A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma, J Clin Oncol. 9: 1811 (1991).PubMedGoogle Scholar
  24. 24.
    L. Danhauser, T. Gilchrist, J. Friemann, A. Markowitz, A. Yeomans, C. Hunter, and J. Gutterman, Effect of recombinant interferon-α2b on the plasma pharmacokinetics of fluorouracil in patients with advanced cancer, Proc Am Assoc Cancer Res. 32: 1052 (1991).Google Scholar
  25. 25.
    C. Lindley, S. Bernard, M. Gavigan, et al, Interferon-alpha increases 5-fluorouracil (5-FU) plasma levels 16-fold within one hour: results of a phase I study, J Interferon Res. 10: 5 (1990).Google Scholar
  26. 26.
    J.A. Sparano, S. Wadler, R. Diasio, R. Spears, E.L. Schwartz, A. Einzig, and P.H. Wiernik, Phase I trial of prolonged infusion 5-fluorouracil and interferon alpha, Proc Am Assoc Cancer Res. 33: 3185 (1992).Google Scholar
  27. 27.
    F. Halberg, E.A. Johnson, W. Nelson, W. Runge, R. Sothern, Autorhythmometry procedures for physiologic self-measurements and their analysis, Physiol Teacher. 1: 1 (1972).Google Scholar
  28. 28.
    B.E. Harris BE, R. Song R, S. Soong S, R.B. Diasio, Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion, Cancer Res. 50: 197 (1990).PubMedGoogle Scholar
  29. 29.
    W.M. Hryniuk, W.M, A. Figueredo, and M. Goodyear, M, Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14 (suppl 4): 3 (1987).PubMedGoogle Scholar
  30. 30.
    M. Findlay, M. Leach, J. Glaholm, et al, Monitoring interferon (Intron A) modulation of 5-fluorouracil in patients with colorectal cancer using 19F magnetic resonance spectroscopy: correlation with clinical effects and implications for further clinical trials, Proc Am Soc Clin Oncol. 11: 495 (1992).Google Scholar
  31. 31.
    S. Wadler, M. Goldman, A. Lyver, P.H. Wiernik, Phase I trial of 5-fluorouracil and recombinant α2b-interferon in patients with advanced cancer, Cancer Res. 50: 2056 (1990).PubMedGoogle Scholar
  32. 32.
    P.I. Clark, M.L. Slevin, R.H. Reznik, et al, Two randomized phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (Trial 1) and in combination with 5-fluorouracil (Trial 2) in advanced colorectal cancer, Int J Colored Dis. 2: 26 (1987).CrossRefGoogle Scholar
  33. 33.
    J.L. Gabrilove, A. Jakubowski, H. Scher, et al, Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due the chemotherapy for transitional-cell carcinoma of the urothelium, N Eng J Med. 318: 1414 (1988).CrossRefGoogle Scholar
  34. 34.
    J.A. Houghton, D.A. Adkins, A. Rahman, PJ. Houghton, Interaction between 5-fluorouracil, [6RS] leucovorin, and recombinant human interferon-α2a in cultured colon adenocarcinoma cells, Cancer Communications. 3: 225 (1991).PubMedGoogle Scholar
  35. 35.
    J. Press, Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer, Semin Oncol. 19: 220 (1992).Google Scholar
  36. 36.
    J.A. Put, P.H.M, de Mulder, J.Th.M. Burghouts, and DJ.Th. Wagener, Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer, Semin Oncol. 19: 208 (1992).Google Scholar
  37. 37.
    HJ. Schmoll, C.H. Kohne-Wompner, W. Hiddemann, et al, Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial, Semin Oncol. 19: 191 (1992).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Joseph A. Sparano
    • 1
  • Scott Wadler
    • 1
  1. 1.Albert Einstein Cancer CenterMontefiore Medical CenterBronxUSA

Personalised recommendations